AZ catches a break: Seroquel XR formulation patent valid and infringed, US judge says
This article was originally published in Scrip
Executive Summary
AstraZeneca has caught a break as a US district court has ruled that the formulation patent for its extended-release version of Seroquel is valid. Unless overturned on appeal, the ruling effectively clears the way for the firm to sell Seroquel XR (extended release quetiapine fumarate) without generic competition in the US until 2017.